Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2014, Article ID 369084, 5 pages
http://dx.doi.org/10.1155/2014/369084
Clinical Study

Determining Risk Factors of Bleeding in Patients on Warfarin Treatment

1Department of Emergency Medicine, Silifke State Hospital, Mersin, Turkey
2Department of Emergency Medicine, Faculty of Medicine, Mersin University, Mersin, Turkey
3Department of Biostatistics, Faculty of Medicine, Mersin University, Mersin, Turkey
4Department of Emergency Medicine, Tepecik Research Hospital, İzmir, Turkey
5Department of Emergency Medicine, State Hospital, Niğde, Turkey
6Department of Emergency Medicine, State Hospital, Balıkesir, Turkey

Received 4 June 2014; Revised 3 October 2014; Accepted 21 October 2014; Published 9 November 2014

Academic Editor: Elvira Grandone

Copyright © 2014 Evren Uygungül et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. R. Olson, “Warfarin and superwarfarin toxicity,” 2013, http://emedicine.medscape.com/article/821038-overview.
  2. S. Schulman, S. Granqvist, M. Holmström et al., “The duration of oral anticoagulant therapy after a second episode of venous thromboembolism,” The New England Journal of Medicine, vol. 336, no. 6, pp. 393–398, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Witt, T. Delate, N. P. Clark et al., “Outcomes and predictors of very stable INR control during chronic anticoagulation therapy,” Blood, vol. 114, no. 5, pp. 952–956, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Miura, T. Nishinaka, T. Terada, and K. Yonezawa, “Relationship between aging and dosage of warfarin: the current status of warfarin anticoagulant therapy for Japanese outpatients in a department of cardiovascular medicine,” Journal of Cardiology, vol. 53, no. 3, pp. 355–360, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. C. Fang, A. S. Go, E. M. Hylek et al., “Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study,” Journal of the American Geriatrics Society, vol. 54, no. 8, pp. 1231–1236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. D. A. Garcia, S. Regan, M. Crowther, and E. M. Hylek, “The risk of hemorrhage among patients with warfarin-associated coagulopathy,” Journal of the American College of Cardiology, vol. 47, no. 4, pp. 804–808, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. R. S. Epstein, T. P. Moyer, R. E. Aubert et al., “Warfarin genotyping reduces hospitalization rates. Results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study),” Journal of the American College of Cardiology, vol. 55, no. 25, pp. 2804–2812, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Wadelius, L. Y. Chen, K. Downes et al., “Common VKORC1 and GGCX polymorphisms associated with warfarin dose,” Pharmacogenomics Journal, vol. 5, no. 4, pp. 262–270, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan, “Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation,” Circulation, vol. 115, no. 21, pp. 2689–2696, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. B. S. Moffett, M. Ung, and L. Bomgaars, “Risk factors for elevated INR values during warfarin therapy in hospitalized pediatric patients,” Pediatric Blood and Cancer, vol. 58, no. 6, pp. 941–944, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. S. L. Aspinall, B. E. DeSanzo, L. E. Trilli, and C. B. Good, “Bleeding risk index in an anticoagulation clinic,” Journal of General Internal Medicine, vol. 20, no. 11, pp. 1008–1013, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. N. A. Limdi, T. M. Beasley, M. F. Baird et al., “Kidney function influences warfarin responsiveness and hemorrhagic complications,” Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 912–921, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. N. A. Limdi, M. A. Limdi, L. Cavallari et al., “Warfarin dosing in patients with impaired kidney function,” Journal of Nephrology, vol. 23, pp. 648–652, 2010. View at Google Scholar
  14. L. E. Hines, D. Ceron-Cabrera, K. Romero et al., “Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs,” Clinical Therapeutics, vol. 33, no. 1, pp. 36–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. M. Galatro, P. C. Adams, M. Cohen, R. McBride, and H. Blanke, “Bleeding complications and INR control of combined warfarin and low-dose aspirin therapy in patients with unstable angina and Non-Q-Wave myocardial infarction,” Journal of Thrombosis and Thrombolysis, vol. 5, no. 3, pp. 249–255, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Gando, S. Nanzaki, S. Sasaki, and O. Kemmotsu, “Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation,” Thrombosis and Haemostasis, vol. 79, no. 6, pp. 1111–1115, 1998. View at Google Scholar · View at Scopus